Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acceptability and Safety of Nirsevimab in infants as per routine immunization practice in Japan (SYMPHONIE 2)
jRCT1041240189Recruiting
- Sponsor
- Sanofi
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nirsevimab in respiratory syncytial virus disease (RSV), sponsored by Sanofi. Primary endpoint: Acceptability of Nirsevimab. Started Feb 2025; status: recruiting.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT1041240189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041240189.